U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06868277) titled 'A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer' on March 07.
Brief Summary: The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Carcinoma, Non-Small Cell Lung
Intervention:
BIOLOGICAL: Rilvegostomig
Administered intravenously (IV) on Day 1 of each 21-day cycle
BIOLOGICAL: Pembrolizumab
Administered intravenously (...